

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

B

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

DATE MAILED:

24

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------

1

EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

24

J
DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

1. The communication filed 11/9/00 is not fully responsive to the communication mailed 8/9/00. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825.

Specifically, Applicant has not identified in the specification all of the sequences in the Sequence Listing. Applicant's amendment to the specification filed 7/31/00 requested deletion of the paragraph which identified the sequences of SEQ ID NO:8-22. The amendment incorrectly stated that the paragraph was at page 59 of the specification. However, page 59 of the specification is the abstract. It is believed that Applicant intended deletion of the paragraph at page 40 of the specification. Hence, the appropriate paragraph at page 40 has been deleted. As a consequence of the deletion, the sequences of SEQ ID NO:8-22 are no longer identified in the specification. Appropriate correction is required.

It is noted that the sequences of SEQ ID NO:14-22 were introduced in the Sequence Listing filed 3/15/00. Applicant indicated that the sequences did not constitute new matter, and indicated that support for the sequences could be found at pages 12 and 13 of the specification. Applicant should amend pages

12 and 13 of the specification to indicate how each of the sequences of SEQ ID NO:14-22 are supported by the cited references.

Since the response appears to be *bona fide*, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is required to complete the response within ONE MONTH.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy J. Nelson whose telephone number is (703) 306-3218. The examiner can normally be reached on Monday-Friday from 8:00 AM -4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Paula Hutzell, can be reached at (703) 308-4310. The fax phone number for this Group is (703) 308-4242 or (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1234.



**AMY J. NELSON, PH.D
PRIMARY EXAMINER**

Amy J. Nelson

December 15, 2000